Immix Biopharma, Inc.
NASDAQ:IMMX
2.18 (USD) • At close December 23, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Immix Biopharma, Inc. |
Symbool | IMMX |
Munteenheid | USD |
Prijs | 2.18 |
Beurswaarde | 59,966,649 |
Dividendpercentage | 0% |
52-weken bereik | 1.26 - 7.46 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. |
Website | https://www.immixbio.com |
An error occurred while fetching data.
Over Immix Biopharma, Inc.
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)